[Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
OBJECTIVE
To investigate the expression of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma (MM), and explore the importance of Notch signaling pathway in the formation and progression of MM.


METHODS
Thirty three MM patients and 15 healthy controls were enrolled in this study. The expression of Notch1 on the membrane of bone marrow CD38(+)CD138(+) and CD38(+)CD138(-) plasma cells were analyzed by flow cytometry. The clinical data of MM patients were also analyzed.


RESULTS
The ratio of Notch1 on the membrane of CD38(+)CD138(+) plasma cells of MM patients was (60.21 ± 25.06)% which was significantly higher than those of CD38(+)CD138(-) plasma cells of MM patients (39.84 ± 18.94)% (P = 0.000) and controls (38.34 ± 19.39)% (P = 0.004). There was no statistical difference between the two latter groups (P > 0.05). The expression of Notch1 on CD38(+)CD138(+)plasma cells from 24 newly diagnosed MM patients was correlated to the level of malignant plasma cells in there bone marrow (r = 0.914, P = 0.000), serum level of lactate dehydrogenase (LDH) (r = 0.754, P = 0.007), and β(2)-MG(r = 0.716, P = 0.013). The ratio of Notch1 on the membrane of CD38(+)CD138(+) plasma cells of MM patients who had renal dysfunction was correlated to their abnormal serum creatinine levels. The expression of Notch1 on CD38(+)CD138(+) plasma cells from 17 MM patients who received VD (bortezamib and dexamethasone) chemotherapy was correlated to the ratio of plasma cell reduction after the first VD chemotherapy (r = 0.842, P = 0.000).


CONCLUSIONS
The expression of Notch1 on the membrane of CD38(+)CD138(+) plasma cells of MM patients was significantly higher than those of CD38(+)CD138(-) plasma cells of MM patients and controls. Notch1 overexpressed plasma cells were sensitive to the early VD therapy, and correlated to the progression and long term outcome of MM.
Department of Hematology, General Hospital, Tianjin Medical University, Tianjin, China.
Yi-ran
YR
Zhao
Rong
R
Fu
Jing
J
Guan
Shan
S
Gao
Hui
H
Liu
Er-bao
EB
Ruan
Wen
W
Qu
Yong
Y
Liang
Guo-jin
GJ
Wang
Xiao-ming
XM
Wang
Hong
H
Liu
Yu-hong
YH
Wu
Jia
J
Song
Hua-quan
HQ
Wang
Li-min
LM
Xing
Jun
J
Wang
Li-juan
LJ
Li
Zong-hong
ZH
Shao
D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000378:metabolism; D016022:Case-Control Studies; D002452:Cell Count; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000378:metabolism*; D010950:Plasma Cells / Q000276:immunology / Q000378:metabolism*; D011379:Prognosis; D051881:Receptor, Notch1 / Q000378:metabolism*; D053668:Syndecan-1 / Q000276:immunology
C497761:NOTCH1 protein, human; D051881:Receptor, Notch1; D053668:Syndecan-1; D051997:ADP-ribosyl Cyclase 1